Articles tagged with Beta Cells
Avandia targets both fundamental causes of type 2 diabetes by reducing insulin resistance and improving beta-cell function, providing enhanced glycaemic control. This dual therapeutic approach may delay disease progression and alter outcomes.
UCSD School of Medicine scientists have successfully cultured human beta cells that can produce insulin indefinitely. The immortal cell line holds promise for treating people with diabetes through transplantation, potentially offering an unlimited source of insulin-producing tissue.
Researchers found that Avandia improves beta cell function, as measured by proinsulin to insulin ratio, indicating potential benefits for long-term glycemic control and disease progression. The study's results support the use of Avandia in type 2 diabetes treatment and suggest its potential to delay disease progression.